APA (7th ed.) Citation

Signorelli, C., Basso, M., Calegari, M. A., Anghelone, A., Passardi, A., Gallio, C., . . . Mazzuca, F. (2025). Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study. Cancers, 17(20), 3316. https://doi.org/10.3390/cancers17203316

Chicago Style (17th ed.) Citation

Signorelli, Carlo, et al. "Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study." Cancers 17, no. 20 (2025): 3316. https://doi.org/10.3390/cancers17203316.

MLA (9th ed.) Citation

Signorelli, Carlo, et al. "Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study." Cancers, vol. 17, no. 20, 2025, p. 3316, https://doi.org/10.3390/cancers17203316.